nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—CYP1A2—Imiquimod—skin cancer	0.109	0.153	CbGbCtD
Aprepitant—CYP2C19—Vismodegib—skin cancer	0.0823	0.115	CbGbCtD
Aprepitant—CYP2C9—Vismodegib—skin cancer	0.0684	0.0956	CbGbCtD
Aprepitant—CYP1A2—Vemurafenib—skin cancer	0.06	0.0839	CbGbCtD
Aprepitant—CYP3A4—Temozolomide—skin cancer	0.0574	0.0802	CbGbCtD
Aprepitant—CYP3A4—Imiquimod—skin cancer	0.0574	0.0802	CbGbCtD
Aprepitant—CYP1A2—Dacarbazine—skin cancer	0.046	0.0643	CbGbCtD
Aprepitant—CYP3A4—Vismodegib—skin cancer	0.0398	0.0556	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0369	0.0515	CbGbCtD
Aprepitant—CYP3A7—Docetaxel—skin cancer	0.0369	0.0515	CbGbCtD
Aprepitant—CYP3A4—Vemurafenib—skin cancer	0.0314	0.0439	CbGbCtD
Aprepitant—CYP3A5—Docetaxel—skin cancer	0.0277	0.0387	CbGbCtD
Aprepitant—CYP1A2—Fluorouracil—skin cancer	0.027	0.0377	CbGbCtD
Aprepitant—CYP2C9—Fluorouracil—skin cancer	0.0243	0.034	CbGbCtD
Aprepitant—CYP3A4—Docetaxel—skin cancer	0.0108	0.0151	CbGbCtD
Aprepitant—TACR3—Peptide GPCRs—MC1R—skin cancer	0.000345	0.109	CbGpPWpGaD
Aprepitant—Angiopathy—Temozolomide—skin cancer	0.000307	0.00109	CcSEcCtD
Aprepitant—Immune system disorder—Temozolomide—skin cancer	0.000306	0.00109	CcSEcCtD
Aprepitant—Mediastinal disorder—Temozolomide—skin cancer	0.000305	0.00108	CcSEcCtD
Aprepitant—Cough—Bleomycin—skin cancer	0.000305	0.00108	CcSEcCtD
Aprepitant—Chills—Temozolomide—skin cancer	0.000304	0.00108	CcSEcCtD
Aprepitant—Dehydration—Docetaxel—skin cancer	0.000303	0.00108	CcSEcCtD
Aprepitant—Ill-defined disorder—Dactinomycin—skin cancer	0.000302	0.00107	CcSEcCtD
Aprepitant—Anaemia—Dactinomycin—skin cancer	0.000301	0.00107	CcSEcCtD
Aprepitant—Vomiting—Vemurafenib—skin cancer	0.000299	0.00106	CcSEcCtD
Aprepitant—Alopecia—Temozolomide—skin cancer	0.000299	0.00106	CcSEcCtD
Aprepitant—Myalgia—Bleomycin—skin cancer	0.000298	0.00106	CcSEcCtD
Aprepitant—Chest pain—Bleomycin—skin cancer	0.000298	0.00106	CcSEcCtD
Aprepitant—Abdominal pain upper—Docetaxel—skin cancer	0.000297	0.00106	CcSEcCtD
Aprepitant—Rash—Vemurafenib—skin cancer	0.000297	0.00106	CcSEcCtD
Aprepitant—Mental disorder—Temozolomide—skin cancer	0.000297	0.00105	CcSEcCtD
Aprepitant—Dermatitis—Vemurafenib—skin cancer	0.000297	0.00105	CcSEcCtD
Aprepitant—Hypersensitivity—Imiquimod—skin cancer	0.000296	0.00105	CcSEcCtD
Aprepitant—Headache—Vemurafenib—skin cancer	0.000295	0.00105	CcSEcCtD
Aprepitant—Malnutrition—Temozolomide—skin cancer	0.000295	0.00105	CcSEcCtD
Aprepitant—Erythema—Temozolomide—skin cancer	0.000295	0.00105	CcSEcCtD
Aprepitant—Breast disorder—Docetaxel—skin cancer	0.000294	0.00105	CcSEcCtD
Aprepitant—Discomfort—Bleomycin—skin cancer	0.000294	0.00104	CcSEcCtD
Aprepitant—Malaise—Dactinomycin—skin cancer	0.000294	0.00104	CcSEcCtD
Aprepitant—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000293	0.00104	CcSEcCtD
Aprepitant—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000293	0.00104	CcSEcCtD
Aprepitant—Cramp muscle—Docetaxel—skin cancer	0.000293	0.00104	CcSEcCtD
Aprepitant—Dysgeusia—Temozolomide—skin cancer	0.000289	0.00103	CcSEcCtD
Aprepitant—Asthenia—Imiquimod—skin cancer	0.000288	0.00102	CcSEcCtD
Aprepitant—Confusional state—Bleomycin—skin cancer	0.000288	0.00102	CcSEcCtD
Aprepitant—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000287	0.00102	CcSEcCtD
Aprepitant—Anaphylactic shock—Bleomycin—skin cancer	0.000285	0.00101	CcSEcCtD
Aprepitant—Oedema—Bleomycin—skin cancer	0.000285	0.00101	CcSEcCtD
Aprepitant—Back pain—Temozolomide—skin cancer	0.000285	0.00101	CcSEcCtD
Aprepitant—Pruritus—Imiquimod—skin cancer	0.000284	0.00101	CcSEcCtD
Aprepitant—Infection—Bleomycin—skin cancer	0.000283	0.00101	CcSEcCtD
Aprepitant—Dysphagia—Docetaxel—skin cancer	0.000281	0.001	CcSEcCtD
Aprepitant—Nausea—Vemurafenib—skin cancer	0.00028	0.000994	CcSEcCtD
Aprepitant—Thrombocytopenia—Bleomycin—skin cancer	0.000279	0.000993	CcSEcCtD
Aprepitant—Myalgia—Dactinomycin—skin cancer	0.000278	0.000986	CcSEcCtD
Aprepitant—Tremor—Temozolomide—skin cancer	0.000276	0.000982	CcSEcCtD
Aprepitant—Alopecia—Fluorouracil—skin cancer	0.000276	0.00098	CcSEcCtD
Aprepitant—Diarrhoea—Imiquimod—skin cancer	0.000275	0.000976	CcSEcCtD
Aprepitant—Discomfort—Dactinomycin—skin cancer	0.000274	0.000975	CcSEcCtD
Aprepitant—Ill-defined disorder—Temozolomide—skin cancer	0.000274	0.000972	CcSEcCtD
Aprepitant—Anaemia—Temozolomide—skin cancer	0.000273	0.000968	CcSEcCtD
Aprepitant—Anorexia—Bleomycin—skin cancer	0.000272	0.000966	CcSEcCtD
Aprepitant—Erythema—Fluorouracil—skin cancer	0.000272	0.000965	CcSEcCtD
Aprepitant—Angioedema—Temozolomide—skin cancer	0.000269	0.000957	CcSEcCtD
Aprepitant—Hypotension—Bleomycin—skin cancer	0.000267	0.000947	CcSEcCtD
Aprepitant—Oedema—Dactinomycin—skin cancer	0.000266	0.000946	CcSEcCtD
Aprepitant—Malaise—Temozolomide—skin cancer	0.000266	0.000945	CcSEcCtD
Aprepitant—Dizziness—Imiquimod—skin cancer	0.000266	0.000944	CcSEcCtD
Aprepitant—Infection—Dactinomycin—skin cancer	0.000264	0.000939	CcSEcCtD
Aprepitant—Neutropenia—Docetaxel—skin cancer	0.000263	0.000935	CcSEcCtD
Aprepitant—Palpitations—Temozolomide—skin cancer	0.000261	0.000926	CcSEcCtD
Aprepitant—Thrombocytopenia—Dactinomycin—skin cancer	0.00026	0.000926	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00026	0.000924	CcSEcCtD
Aprepitant—Cough—Temozolomide—skin cancer	0.000257	0.000914	CcSEcCtD
Aprepitant—Paraesthesia—Bleomycin—skin cancer	0.000256	0.00091	CcSEcCtD
Aprepitant—Weight increased—Docetaxel—skin cancer	0.000256	0.00091	CcSEcCtD
Aprepitant—Convulsion—Temozolomide—skin cancer	0.000255	0.000908	CcSEcCtD
Aprepitant—Vomiting—Imiquimod—skin cancer	0.000255	0.000907	CcSEcCtD
Aprepitant—Weight decreased—Docetaxel—skin cancer	0.000255	0.000905	CcSEcCtD
Aprepitant—Hypertension—Temozolomide—skin cancer	0.000255	0.000905	CcSEcCtD
Aprepitant—Dyspnoea—Bleomycin—skin cancer	0.000254	0.000904	CcSEcCtD
Aprepitant—Anorexia—Dactinomycin—skin cancer	0.000254	0.000901	CcSEcCtD
Aprepitant—Rash—Imiquimod—skin cancer	0.000253	0.0009	CcSEcCtD
Aprepitant—Dermatitis—Imiquimod—skin cancer	0.000253	0.000899	CcSEcCtD
Aprepitant—Pneumonia—Docetaxel—skin cancer	0.000252	0.000897	CcSEcCtD
Aprepitant—Headache—Imiquimod—skin cancer	0.000252	0.000894	CcSEcCtD
Aprepitant—Anaemia—Fluorouracil—skin cancer	0.000251	0.000892	CcSEcCtD
Aprepitant—Arthralgia—Temozolomide—skin cancer	0.000251	0.000892	CcSEcCtD
Aprepitant—Myalgia—Temozolomide—skin cancer	0.000251	0.000892	CcSEcCtD
Aprepitant—Infestation—Docetaxel—skin cancer	0.000251	0.000892	CcSEcCtD
Aprepitant—Infestation NOS—Docetaxel—skin cancer	0.000251	0.000892	CcSEcCtD
Aprepitant—Anxiety—Temozolomide—skin cancer	0.00025	0.000889	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000249	0.000886	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000249	0.000884	CcSEcCtD
Aprepitant—Discomfort—Temozolomide—skin cancer	0.000248	0.000881	CcSEcCtD
Aprepitant—Decreased appetite—Bleomycin—skin cancer	0.000248	0.000881	CcSEcCtD
Aprepitant—Acute coronary syndrome—Docetaxel—skin cancer	0.000247	0.000879	CcSEcCtD
Aprepitant—Renal failure—Docetaxel—skin cancer	0.000247	0.000877	CcSEcCtD
Aprepitant—Myocardial infarction—Docetaxel—skin cancer	0.000246	0.000874	CcSEcCtD
Aprepitant—Neuropathy peripheral—Docetaxel—skin cancer	0.000246	0.000874	CcSEcCtD
Aprepitant—Dry mouth—Temozolomide—skin cancer	0.000245	0.000872	CcSEcCtD
Aprepitant—Stomatitis—Docetaxel—skin cancer	0.000245	0.000869	CcSEcCtD
Aprepitant—Pain—Bleomycin—skin cancer	0.000244	0.000867	CcSEcCtD
Aprepitant—Conjunctivitis—Docetaxel—skin cancer	0.000244	0.000867	CcSEcCtD
Aprepitant—Confusional state—Temozolomide—skin cancer	0.000243	0.000862	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000242	0.000861	CcSEcCtD
Aprepitant—Anaphylactic shock—Temozolomide—skin cancer	0.000241	0.000855	CcSEcCtD
Aprepitant—Oedema—Temozolomide—skin cancer	0.000241	0.000855	CcSEcCtD
Aprepitant—Infection—Temozolomide—skin cancer	0.000239	0.00085	CcSEcCtD
Aprepitant—Nausea—Imiquimod—skin cancer	0.000239	0.000848	CcSEcCtD
Aprepitant—Nervous system disorder—Temozolomide—skin cancer	0.000236	0.000839	CcSEcCtD
Aprepitant—Thrombocytopenia—Temozolomide—skin cancer	0.000236	0.000837	CcSEcCtD
Aprepitant—Convulsion—Fluorouracil—skin cancer	0.000235	0.000837	CcSEcCtD
Aprepitant—Feeling abnormal—Bleomycin—skin cancer	0.000235	0.000835	CcSEcCtD
Aprepitant—Skin disorder—Temozolomide—skin cancer	0.000234	0.000831	CcSEcCtD
Aprepitant—Hyperhidrosis—Temozolomide—skin cancer	0.000233	0.000827	CcSEcCtD
Aprepitant—Myalgia—Fluorouracil—skin cancer	0.000231	0.000822	CcSEcCtD
Aprepitant—Chest pain—Fluorouracil—skin cancer	0.000231	0.000822	CcSEcCtD
Aprepitant—Decreased appetite—Dactinomycin—skin cancer	0.000231	0.000822	CcSEcCtD
Aprepitant—Fatigue—Dactinomycin—skin cancer	0.000229	0.000815	CcSEcCtD
Aprepitant—Anorexia—Temozolomide—skin cancer	0.000229	0.000815	CcSEcCtD
Aprepitant—Discomfort—Fluorouracil—skin cancer	0.000229	0.000812	CcSEcCtD
Aprepitant—Pain—Dactinomycin—skin cancer	0.000228	0.000809	CcSEcCtD
Aprepitant—Urticaria—Bleomycin—skin cancer	0.000227	0.000805	CcSEcCtD
Aprepitant—Body temperature increased—Bleomycin—skin cancer	0.000226	0.000801	CcSEcCtD
Aprepitant—Hypoaesthesia—Docetaxel—skin cancer	0.000224	0.000796	CcSEcCtD
Aprepitant—Confusional state—Fluorouracil—skin cancer	0.000224	0.000795	CcSEcCtD
Aprepitant—Pharyngitis—Docetaxel—skin cancer	0.000224	0.000794	CcSEcCtD
Aprepitant—Urinary tract disorder—Docetaxel—skin cancer	0.000222	0.000791	CcSEcCtD
Aprepitant—Anaphylactic shock—Fluorouracil—skin cancer	0.000222	0.000788	CcSEcCtD
Aprepitant—Oedema—Fluorouracil—skin cancer	0.000222	0.000788	CcSEcCtD
Aprepitant—Connective tissue disorder—Docetaxel—skin cancer	0.000221	0.000787	CcSEcCtD
Aprepitant—Urethral disorder—Docetaxel—skin cancer	0.000221	0.000785	CcSEcCtD
Aprepitant—Infection—Fluorouracil—skin cancer	0.00022	0.000783	CcSEcCtD
Aprepitant—Feeling abnormal—Dactinomycin—skin cancer	0.000219	0.000779	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000219	0.000779	CcSEcCtD
Aprepitant—Insomnia—Temozolomide—skin cancer	0.000218	0.000773	CcSEcCtD
Aprepitant—Gastrointestinal pain—Dactinomycin—skin cancer	0.000218	0.000773	CcSEcCtD
Aprepitant—Nervous system disorder—Fluorouracil—skin cancer	0.000217	0.000773	CcSEcCtD
Aprepitant—Thrombocytopenia—Fluorouracil—skin cancer	0.000217	0.000771	CcSEcCtD
Aprepitant—Tachycardia—Fluorouracil—skin cancer	0.000216	0.000769	CcSEcCtD
Aprepitant—Paraesthesia—Temozolomide—skin cancer	0.000216	0.000768	CcSEcCtD
Aprepitant—Dyspnoea—Temozolomide—skin cancer	0.000215	0.000762	CcSEcCtD
Aprepitant—Somnolence—Temozolomide—skin cancer	0.000214	0.00076	CcSEcCtD
Aprepitant—Erythema multiforme—Docetaxel—skin cancer	0.000213	0.000757	CcSEcCtD
Aprepitant—Dyspepsia—Temozolomide—skin cancer	0.000212	0.000753	CcSEcCtD
Aprepitant—Anorexia—Fluorouracil—skin cancer	0.000211	0.000751	CcSEcCtD
Aprepitant—Eye disorder—Docetaxel—skin cancer	0.00021	0.000748	CcSEcCtD
Aprepitant—Abdominal pain—Dactinomycin—skin cancer	0.00021	0.000747	CcSEcCtD
Aprepitant—Body temperature increased—Dactinomycin—skin cancer	0.00021	0.000747	CcSEcCtD
Aprepitant—Hypersensitivity—Bleomycin—skin cancer	0.00021	0.000747	CcSEcCtD
Aprepitant—Decreased appetite—Temozolomide—skin cancer	0.000209	0.000743	CcSEcCtD
Aprepitant—Cardiac disorder—Docetaxel—skin cancer	0.000209	0.000743	CcSEcCtD
Aprepitant—Flushing—Docetaxel—skin cancer	0.000209	0.000743	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Temozolomide—skin cancer	0.000208	0.000738	CcSEcCtD
Aprepitant—Fatigue—Temozolomide—skin cancer	0.000207	0.000737	CcSEcCtD
Aprepitant—Hypotension—Fluorouracil—skin cancer	0.000207	0.000736	CcSEcCtD
Aprepitant—Pain—Temozolomide—skin cancer	0.000206	0.000731	CcSEcCtD
Aprepitant—Constipation—Temozolomide—skin cancer	0.000206	0.000731	CcSEcCtD
Aprepitant—Asthenia—Bleomycin—skin cancer	0.000205	0.000727	CcSEcCtD
Aprepitant—Angiopathy—Docetaxel—skin cancer	0.000204	0.000726	CcSEcCtD
Aprepitant—Immune system disorder—Docetaxel—skin cancer	0.000203	0.000723	CcSEcCtD
Aprepitant—Mediastinal disorder—Docetaxel—skin cancer	0.000203	0.000721	CcSEcCtD
Aprepitant—Chills—Docetaxel—skin cancer	0.000202	0.000718	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000202	0.000718	CcSEcCtD
Aprepitant—Pruritus—Bleomycin—skin cancer	0.000202	0.000717	CcSEcCtD
Aprepitant—Insomnia—Fluorouracil—skin cancer	0.000201	0.000713	CcSEcCtD
Aprepitant—Paraesthesia—Fluorouracil—skin cancer	0.000199	0.000708	CcSEcCtD
Aprepitant—Alopecia—Docetaxel—skin cancer	0.000199	0.000707	CcSEcCtD
Aprepitant—Feeling abnormal—Temozolomide—skin cancer	0.000198	0.000705	CcSEcCtD
Aprepitant—Dyspnoea—Fluorouracil—skin cancer	0.000198	0.000702	CcSEcCtD
Aprepitant—Mental disorder—Docetaxel—skin cancer	0.000197	0.000701	CcSEcCtD
Aprepitant—Somnolence—Fluorouracil—skin cancer	0.000197	0.0007	CcSEcCtD
Aprepitant—Gastrointestinal pain—Temozolomide—skin cancer	0.000197	0.000699	CcSEcCtD
Aprepitant—Malnutrition—Docetaxel—skin cancer	0.000196	0.000697	CcSEcCtD
Aprepitant—Erythema—Docetaxel—skin cancer	0.000196	0.000697	CcSEcCtD
Aprepitant—Hypersensitivity—Dactinomycin—skin cancer	0.000196	0.000697	CcSEcCtD
Aprepitant—Dyspepsia—Fluorouracil—skin cancer	0.000195	0.000694	CcSEcCtD
Aprepitant—Decreased appetite—Fluorouracil—skin cancer	0.000193	0.000685	CcSEcCtD
Aprepitant—Dysgeusia—Docetaxel—skin cancer	0.000192	0.000682	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000191	0.00068	CcSEcCtD
Aprepitant—Urticaria—Temozolomide—skin cancer	0.000191	0.000679	CcSEcCtD
Aprepitant—Asthenia—Dactinomycin—skin cancer	0.000191	0.000678	CcSEcCtD
Aprepitant—Body temperature increased—Temozolomide—skin cancer	0.00019	0.000676	CcSEcCtD
Aprepitant—Abdominal pain—Temozolomide—skin cancer	0.00019	0.000676	CcSEcCtD
Aprepitant—Back pain—Docetaxel—skin cancer	0.00019	0.000674	CcSEcCtD
Aprepitant—Pain—Fluorouracil—skin cancer	0.00019	0.000674	CcSEcCtD
Aprepitant—Muscle spasms—Docetaxel—skin cancer	0.000189	0.00067	CcSEcCtD
Aprepitant—Feeling abnormal—Fluorouracil—skin cancer	0.000183	0.000649	CcSEcCtD
Aprepitant—Diarrhoea—Dactinomycin—skin cancer	0.000182	0.000647	CcSEcCtD
Aprepitant—Vomiting—Bleomycin—skin cancer	0.000181	0.000645	CcSEcCtD
Aprepitant—Anaemia—Docetaxel—skin cancer	0.000181	0.000644	CcSEcCtD
Aprepitant—Rash—Bleomycin—skin cancer	0.00018	0.000639	CcSEcCtD
Aprepitant—Dermatitis—Bleomycin—skin cancer	0.00018	0.000639	CcSEcCtD
Aprepitant—Hypersensitivity—Temozolomide—skin cancer	0.000177	0.00063	CcSEcCtD
Aprepitant—Urticaria—Fluorouracil—skin cancer	0.000176	0.000626	CcSEcCtD
Aprepitant—Syncope—Docetaxel—skin cancer	0.000176	0.000625	CcSEcCtD
Aprepitant—Body temperature increased—Fluorouracil—skin cancer	0.000175	0.000623	CcSEcCtD
Aprepitant—Palpitations—Docetaxel—skin cancer	0.000173	0.000616	CcSEcCtD
Aprepitant—Asthenia—Temozolomide—skin cancer	0.000173	0.000614	CcSEcCtD
Aprepitant—Loss of consciousness—Docetaxel—skin cancer	0.000172	0.000612	CcSEcCtD
Aprepitant—Cough—Docetaxel—skin cancer	0.000171	0.000608	CcSEcCtD
Aprepitant—Pruritus—Temozolomide—skin cancer	0.00017	0.000605	CcSEcCtD
Aprepitant—Convulsion—Docetaxel—skin cancer	0.00017	0.000604	CcSEcCtD
Aprepitant—Nausea—Bleomycin—skin cancer	0.000169	0.000602	CcSEcCtD
Aprepitant—Hypertension—Docetaxel—skin cancer	0.000169	0.000602	CcSEcCtD
Aprepitant—Vomiting—Dactinomycin—skin cancer	0.000169	0.000601	CcSEcCtD
Aprepitant—TACR1—Peptide GPCRs—MC1R—skin cancer	0.000169	0.0531	CbGpPWpGaD
Aprepitant—Rash—Dactinomycin—skin cancer	0.000168	0.000596	CcSEcCtD
Aprepitant—Chest pain—Docetaxel—skin cancer	0.000167	0.000593	CcSEcCtD
Aprepitant—Myalgia—Docetaxel—skin cancer	0.000167	0.000593	CcSEcCtD
Aprepitant—Arthralgia—Docetaxel—skin cancer	0.000167	0.000593	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000166	0.000589	CcSEcCtD
Aprepitant—Diarrhoea—Temozolomide—skin cancer	0.000165	0.000585	CcSEcCtD
Aprepitant—Hypersensitivity—Fluorouracil—skin cancer	0.000163	0.000581	CcSEcCtD
Aprepitant—Dry mouth—Docetaxel—skin cancer	0.000163	0.00058	CcSEcCtD
Aprepitant—TACR3—Peptide ligand-binding receptors—MC1R—skin cancer	0.000162	0.0511	CbGpPWpGaD
Aprepitant—Confusional state—Docetaxel—skin cancer	0.000161	0.000573	CcSEcCtD
Aprepitant—Anaphylactic shock—Docetaxel—skin cancer	0.00016	0.000569	CcSEcCtD
Aprepitant—Oedema—Docetaxel—skin cancer	0.00016	0.000569	CcSEcCtD
Aprepitant—Dizziness—Temozolomide—skin cancer	0.000159	0.000566	CcSEcCtD
Aprepitant—Infection—Docetaxel—skin cancer	0.000159	0.000565	CcSEcCtD
Aprepitant—Nausea—Dactinomycin—skin cancer	0.000158	0.000562	CcSEcCtD
Aprepitant—Shock—Docetaxel—skin cancer	0.000157	0.00056	CcSEcCtD
Aprepitant—Nervous system disorder—Docetaxel—skin cancer	0.000157	0.000558	CcSEcCtD
Aprepitant—Pruritus—Fluorouracil—skin cancer	0.000157	0.000557	CcSEcCtD
Aprepitant—Thrombocytopenia—Docetaxel—skin cancer	0.000157	0.000557	CcSEcCtD
Aprepitant—Tachycardia—Docetaxel—skin cancer	0.000156	0.000555	CcSEcCtD
Aprepitant—Skin disorder—Docetaxel—skin cancer	0.000155	0.000552	CcSEcCtD
Aprepitant—Vomiting—Temozolomide—skin cancer	0.000153	0.000544	CcSEcCtD
Aprepitant—Anorexia—Docetaxel—skin cancer	0.000153	0.000542	CcSEcCtD
Aprepitant—Rash—Temozolomide—skin cancer	0.000152	0.000539	CcSEcCtD
Aprepitant—Diarrhoea—Fluorouracil—skin cancer	0.000152	0.000539	CcSEcCtD
Aprepitant—Dermatitis—Temozolomide—skin cancer	0.000152	0.000539	CcSEcCtD
Aprepitant—Headache—Temozolomide—skin cancer	0.000151	0.000536	CcSEcCtD
Aprepitant—Hypotension—Docetaxel—skin cancer	0.00015	0.000531	CcSEcCtD
Aprepitant—Dizziness—Fluorouracil—skin cancer	0.000147	0.000521	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000146	0.000518	CcSEcCtD
Aprepitant—Insomnia—Docetaxel—skin cancer	0.000145	0.000514	CcSEcCtD
Aprepitant—Paraesthesia—Docetaxel—skin cancer	0.000144	0.000511	CcSEcCtD
Aprepitant—Nausea—Temozolomide—skin cancer	0.000143	0.000508	CcSEcCtD
Aprepitant—Dyspnoea—Docetaxel—skin cancer	0.000143	0.000507	CcSEcCtD
Aprepitant—Somnolence—Docetaxel—skin cancer	0.000142	0.000506	CcSEcCtD
Aprepitant—Vomiting—Fluorouracil—skin cancer	0.000141	0.000501	CcSEcCtD
Aprepitant—Dyspepsia—Docetaxel—skin cancer	0.000141	0.000501	CcSEcCtD
Aprepitant—Rash—Fluorouracil—skin cancer	0.00014	0.000497	CcSEcCtD
Aprepitant—Dermatitis—Fluorouracil—skin cancer	0.00014	0.000496	CcSEcCtD
Aprepitant—Decreased appetite—Docetaxel—skin cancer	0.000139	0.000494	CcSEcCtD
Aprepitant—Headache—Fluorouracil—skin cancer	0.000139	0.000494	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Docetaxel—skin cancer	0.000138	0.000491	CcSEcCtD
Aprepitant—Fatigue—Docetaxel—skin cancer	0.000138	0.00049	CcSEcCtD
Aprepitant—Pain—Docetaxel—skin cancer	0.000137	0.000486	CcSEcCtD
Aprepitant—Constipation—Docetaxel—skin cancer	0.000137	0.000486	CcSEcCtD
Aprepitant—Feeling abnormal—Docetaxel—skin cancer	0.000132	0.000469	CcSEcCtD
Aprepitant—Nausea—Fluorouracil—skin cancer	0.000132	0.000468	CcSEcCtD
Aprepitant—Gastrointestinal pain—Docetaxel—skin cancer	0.000131	0.000465	CcSEcCtD
Aprepitant—Body temperature increased—Docetaxel—skin cancer	0.000126	0.00045	CcSEcCtD
Aprepitant—Abdominal pain—Docetaxel—skin cancer	0.000126	0.00045	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—CSPG4—skin cancer	0.000122	0.0383	CbGpPWpGaD
Aprepitant—Hypersensitivity—Docetaxel—skin cancer	0.000118	0.000419	CcSEcCtD
Aprepitant—Asthenia—Docetaxel—skin cancer	0.000115	0.000408	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—PTCH2—skin cancer	0.000115	0.0361	CbGpPWpGaD
Aprepitant—Pruritus—Docetaxel—skin cancer	0.000113	0.000402	CcSEcCtD
Aprepitant—Diarrhoea—Docetaxel—skin cancer	0.000109	0.000389	CcSEcCtD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000109	0.0343	CbGpPWpGaD
Aprepitant—Dizziness—Docetaxel—skin cancer	0.000106	0.000376	CcSEcCtD
Aprepitant—Vomiting—Docetaxel—skin cancer	0.000102	0.000362	CcSEcCtD
Aprepitant—Rash—Docetaxel—skin cancer	0.000101	0.000359	CcSEcCtD
Aprepitant—Dermatitis—Docetaxel—skin cancer	0.000101	0.000358	CcSEcCtD
Aprepitant—Headache—Docetaxel—skin cancer	0.0001	0.000356	CcSEcCtD
Aprepitant—Nausea—Docetaxel—skin cancer	9.5e-05	0.000338	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—MC1R—skin cancer	8.3e-05	0.0261	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—MC1R—skin cancer	7.93e-05	0.025	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	7.17e-05	0.0225	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—RHOU—skin cancer	7.13e-05	0.0224	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—SHH—skin cancer	5.91e-05	0.0186	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—PTCH2—skin cancer	5.89e-05	0.0185	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—PTCH1—skin cancer	5.61e-05	0.0176	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—SMO—skin cancer	5.61e-05	0.0176	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—PTCH2—skin cancer	5.61e-05	0.0176	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—PTGER4—skin cancer	5.46e-05	0.0172	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	5.32e-05	0.0167	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—MC1R—skin cancer	4.69e-05	0.0148	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—MC1R—skin cancer	4.26e-05	0.0134	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—MC1R—skin cancer	4.05e-05	0.0127	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—CDK4—skin cancer	4.03e-05	0.0127	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	3.5e-05	0.011	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RHOU—skin cancer	3.48e-05	0.0109	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PTCH2—skin cancer	3.48e-05	0.0109	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—PTGER4—skin cancer	3.08e-05	0.0097	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—SHH—skin cancer	3.03e-05	0.00955	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—SHH—skin cancer	2.89e-05	0.00908	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—PTGS2—skin cancer	2.88e-05	0.00907	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PTCH2—skin cancer	2.88e-05	0.00905	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—PTCH1—skin cancer	2.88e-05	0.00905	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—SMO—skin cancer	2.88e-05	0.00905	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	2.84e-05	0.00894	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—PTGER4—skin cancer	2.8e-05	0.00881	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—SMO—skin cancer	2.74e-05	0.00861	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—PTCH1—skin cancer	2.74e-05	0.00861	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—PTGER4—skin cancer	2.67e-05	0.00838	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—GLI2—skin cancer	2.64e-05	0.0083	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MC1R—skin cancer	2.52e-05	0.00791	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—GLI1—skin cancer	2.48e-05	0.0078	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	2.45e-05	0.00769	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SUFU—skin cancer	2.35e-05	0.00739	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—MC1R—skin cancer	2.29e-05	0.0072	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—MC1R—skin cancer	2.08e-05	0.00654	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.08e-05	0.00654	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.99e-05	0.00626	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SHH—skin cancer	1.79e-05	0.00564	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—RASA1—skin cancer	1.78e-05	0.0056	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—TP53—skin cancer	1.72e-05	0.0054	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTCH2—skin cancer	1.7e-05	0.00535	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PTCH1—skin cancer	1.7e-05	0.00535	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SMO—skin cancer	1.7e-05	0.00535	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PTGER4—skin cancer	1.65e-05	0.0052	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—IL6—skin cancer	1.57e-05	0.00494	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—PTGER4—skin cancer	1.51e-05	0.00474	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—SHH—skin cancer	1.48e-05	0.00466	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—FOXO4—skin cancer	1.46e-05	0.0046	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—SMO—skin cancer	1.4e-05	0.00442	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PTCH1—skin cancer	1.4e-05	0.00442	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.39e-05	0.00437	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PTGER4—skin cancer	1.37e-05	0.0043	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—GLI2—skin cancer	1.29e-05	0.00405	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL6—skin cancer	1.26e-05	0.00395	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MC1R—skin cancer	1.23e-05	0.00386	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—GLI1—skin cancer	1.21e-05	0.00381	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.19e-05	0.00376	CbGpPWpGaD
Aprepitant—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	1.15e-05	0.00362	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SUFU—skin cancer	1.15e-05	0.00361	CbGpPWpGaD
Aprepitant—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	1.05e-05	0.0033	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.02e-05	0.00319	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TERT—skin cancer	9.76e-06	0.00307	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	9.72e-06	0.00306	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	9.57e-06	0.00301	CbGpPWpGaD
Aprepitant—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	8.96e-06	0.00282	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SHH—skin cancer	8.76e-06	0.00275	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RASA1—skin cancer	8.7e-06	0.00274	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	8.61e-06	0.00271	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTCH1—skin cancer	8.3e-06	0.00261	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SMO—skin cancer	8.3e-06	0.00261	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—NRAS—skin cancer	8.22e-06	0.00259	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTGER4—skin cancer	8.08e-06	0.00254	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	7.85e-06	0.00247	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—BRAF—skin cancer	7.73e-06	0.00243	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	7.45e-06	0.00234	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—FOXO4—skin cancer	7.14e-06	0.00224	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—KRAS—skin cancer	7.08e-06	0.00223	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PLIN2—skin cancer	6.86e-06	0.00216	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	6.71e-06	0.00211	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	6.41e-06	0.00202	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—HRAS—skin cancer	6.02e-06	0.00189	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—IL6—skin cancer	5.76e-06	0.00181	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CSPG4—skin cancer	5.53e-06	0.00174	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	5.45e-06	0.00171	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PLIN2—skin cancer	4.96e-06	0.00156	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—NRAS—skin cancer	4.86e-06	0.00153	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TERT—skin cancer	4.77e-06	0.0015	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—KRAS—skin cancer	4.18e-06	0.00132	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—NRAS—skin cancer	4.02e-06	0.00126	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CSPG4—skin cancer	4e-06	0.00126	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PLIN2—skin cancer	3.83e-06	0.00121	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—BRAF—skin cancer	3.78e-06	0.00119	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ENO2—skin cancer	3.76e-06	0.00118	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TP53—skin cancer	3.72e-06	0.00117	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—HRAS—skin cancer	3.55e-06	0.00112	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PLIN2—skin cancer	3.5e-06	0.0011	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—KRAS—skin cancer	3.46e-06	0.00109	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL6—skin cancer	3.4e-06	0.00107	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CSPG4—skin cancer	3.09e-06	0.000972	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PLIN2—skin cancer	2.99e-06	0.00094	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—HRAS—skin cancer	2.94e-06	0.000924	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CSPG4—skin cancer	2.82e-06	0.000886	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL6—skin cancer	2.81e-06	0.000884	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ENO2—skin cancer	2.72e-06	0.000855	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CSPG4—skin cancer	2.41e-06	0.000757	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NRAS—skin cancer	2.37e-06	0.000746	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PLIN2—skin cancer	2.31e-06	0.000725	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ERCC2—skin cancer	2.18e-06	0.000687	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ENO2—skin cancer	2.1e-06	0.000661	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KRAS—skin cancer	2.04e-06	0.000642	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ENO2—skin cancer	1.92e-06	0.000602	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CSPG4—skin cancer	1.86e-06	0.000584	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—skin cancer	1.81e-06	0.000571	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HRAS—skin cancer	1.74e-06	0.000546	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL6—skin cancer	1.66e-06	0.000522	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.64e-06	0.000517	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ENO2—skin cancer	1.64e-06	0.000515	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ERCC2—skin cancer	1.58e-06	0.000496	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.5e-06	0.000471	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTGS2—skin cancer	1.31e-06	0.000412	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.28e-06	0.000403	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ENO2—skin cancer	1.26e-06	0.000397	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ERCC2—skin cancer	1.22e-06	0.000384	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ERCC2—skin cancer	1.11e-06	0.00035	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ERCC2—skin cancer	9.51e-07	0.000299	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTGS2—skin cancer	9.46e-07	0.000298	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ERCC2—skin cancer	7.34e-07	0.000231	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTGS2—skin cancer	7.32e-07	0.00023	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTGS2—skin cancer	6.67e-07	0.00021	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTGS2—skin cancer	5.7e-07	0.000179	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTGS2—skin cancer	4.4e-07	0.000138	CbGpPWpGaD
